Queen Mary University of London
qmul.ac.ukLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
249
Active
75
Phase 3
17
Total enrollment
553,764
Pipeline matrix
Showing 39 of 39 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Rifampicin | — | — | — | — | — | 1 | |
| Azithromycin | — | — | — | — | — | 1 | |
| Isoniazid | — | — | — | — | — | 1 | |
| Pyridoxine Hydrochloride | — | — | — | — | — | 1 | |
| Rivaroxaban | — | — | — | — | — | 1 | |
| Apixaban | — | — | — | — | — | 1 | |
| Enoxaparin Injectable Solution | — | — | — | — | — | 1 | |
| Tinzaparin Injectable Solution | — | — | — | — | — | 1 | |
| Dalteparin Injectable Solution | — | — | — | — | — | 1 | |
| Fondaparinux Injectable Product | — | — | — | — | — | 1 | |
| Cladribine | — | — | — | — | — | 1 | |
| Atezolizumab | — | — | — | — | 4 | ||
| Paclitaxel | — | — | — | — | — | 3 | |
| Gemcitabine | — | — | — | — | — | 2 | |
| Ipatasertib | — | — | — | — | — | 2 | |
| Datopotamab Deruxtecan | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 | |
| Avelumab | — | — | — | — | — | 1 | |
| Continue rivaroxaban or apixaban or warfarin | — | — | — | — | — | 1 | |
| Discontinue rivaroxaban or apixaban or warfarin | — | — | — | — | — | 1 | |
| Doxorubicin | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 1 | |
| Tyruko Injectable Product | — | — | — | — | — | 1 | |
| ATRA | — | — | — | — | — | 1 | |
| nab-paclitaxel | — | — | — | — | — | 1 | |
| COVID-19 vaccine | — | — | — | — | — | 1 | |
| Concentrate beetroot Juice | — | — | — | — | — | 1 | |
| Nitrate-deplete beetroot juice | — | — | — | — | — | 1 | |
| Cantharidin | — | — | — | — | — | 2 | |
| Carboplatin AUC10 | — | — | — | — | — | 1 | |
| Genetic testing for Cancer Susceptibility Genes (CSGs) (BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2, MLH1, MSH2, MSH6) and personalised breast and ovarian cancer risk | — | — | — | — | — | 1 | |
| Assessment of Biological factors | — | — | — | — | — | 1 | |
| Assessment of Genetics | — | — | — | — | — | 1 | |
| Racecadotril 100 milligram (MG) Oral | — | — | — | — | — | 1 | |
| Periodontal Access Flap | — | — | — | — | — | 1 | |
| Epclusa (nucleotide HCV NS5B polymerase inhibitors). | — | — | — | — | — | 1 | |
| Hyaluronic Acid (HA) and Octenidine gel | — | — | — | — | — | 1 | |
| Patients in hospitals allocated to this arm will receive aspirin as their routine thromboprophylaxis after surgery. | — | — | — | — | — | 1 | |
| Low molecular weight heparin | — | — | — | — | — | 1 |
Next readouts
- 2026-02-01
- 2026-04-30
- 2026-05-30
- 2026-08-15
- 2026-08-31
- 2026-12
- 2027-06-30
- 2027-09-01
- 2027-09-30
- 2027-10-31
Top conditions
- Breast Cancer8
- Multiple Sclerosis8
- Cardiovascular Diseases8
- Hypertension7
- Smoking Cessation6
- Myocardial Infarction6
- Periodontitis5
- Primary Aldosteronism4
Frequently asked questions about Queen Mary University of London
- How many clinical trials does Queen Mary University of London have on ClinicalTrials.gov?
- Queen Mary University of London is listed as the lead sponsor on 249 clinical trials in ClinicalTrials.gov, 75 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Queen Mary University of London's trials are in Phase 3?
- 17 of Queen Mary University of London's trials are in Phase 3, spread across 39 active drug programs.
- What therapeutic areas does Queen Mary University of London focus on?
- Queen Mary University of London's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Multiple Sclerosis, Cardiovascular Diseases, Hypertension, Smoking Cessation.
- When are Queen Mary University of London's next clinical trial readouts?
- Queen Mary University of London has 10 upcoming primary-completion readouts tracked here; the soonest is “Influence of NEP Inhibition on Vascular Leak and Inflammation (NEPi-INFLAMMATION)”, expected around 2026-02-01.